Astral Systems has invented and demonstrated the first of its kind multi-state fusion device, enabling orders of magnitude improved fusion rates on a reactor architecture that embodies a quarter century of engineering design. Their small, modular nuclear fusion reactors are compact in size with high particle flux and unparalleled lifetime performance. Astral are applying this technology across medicine and industrial disciplines.

Why we invested

Astral are one of the few companies globally to commercialise nuclear fusion. Their breakthrough technology, Lattice Confinement Fusion, has been validated by some of the world’s most sophisticated buyers, and, as it stands, represents an opportunity to solve a range of problems across critical industries.

Astral’s chosen application is an important one: the radiopharmaceutical industry is looking like one of the most important aspects in the fight against cancer. However, radiopharmaceuticals rely on radioactive isotopes and these isotopes have historically been made in a handful of nuclear fission reactors across Europe. As these fission reactors are decomissioned, an already delicate supply chain is at it’s most critical point as demand for these materials skyrockets.

Astral’s technology allows them to fill the supply/demand gap: serving the radiopharmaceutical industry with the critical materials they need to continue to innovate on cancer treatment.